Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis

Mahmood Moosazadeh; Fatemeh Nabinezhad-Male; Mahdi Afshari; Mohammad Mehdi Nasehi; Mohammad Shabani; Motahareh Kheradmand; Iraj Aghaei; Mahmood Moosazadeh; Fatemeh Nabinezhad-Male; Mahdi Afshari; Mohammad Mehdi Nasehi; Mohammad Shabani; Motahareh Kheradmand; Iraj Aghaei

doi:10.3934/Neuroscience.2021013

AIMS Neuroscience

2021, Volume 8, Issue 2: 239-253. doi: 10.3934/Neuroscience.2021013

Previous Article Next Article

Review

Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis

Running title: Vitamin D status and MS disability

1.
Gastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
2.
Mazandaran University of Medical Sciences, Sari, Iran
3.
Department of Community Medicine, Zabol University of Medical Sciences, Zabol, Iran
4.
Pediatric Neurology Department, Mofid Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5.
Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
6.
Health Science Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran
7.
Neuroscience Research Center, Guilan University of Medical Sciences, Rasht, Iran

Received: 08 November 2020 Accepted: 29 January 2021 Published: 05 February 2021

Association between the serum vitamin D level and disability of patients with multiple sclerosis (MS) has been investigated during several researches. However, these studies reported different results. The current study aims to estimate the correlation between the concentrations of 25 (OH) vitamin D and the level of disability among MS patients. Using Mesh and non-Mesh terms related to MS, disability level and vitamin D, different data banks were searched. Required information was extracted from the selected eligible primary articles. Stata version 11 software was applied for combining the primary correlation coefficients using random effect model. The effect of MS type and patients' age was assessed using meta-regression models. Sensitivity analysis was performed to investigate the role of each primary study in the pooled estimate. Egger test was applied to find any publication bias. Of 14 eligible studies, the total correlation coefficient (95% confidence interval) between 25 (OH) vitamin D level and disability in both sexes as well as among female was estimated as of −0.29 (−0.40, −0.17) and −0.35 (−0.46, −0.24) respectively. Two articles carried out among male did not report significant results. Our meta-analysis showed a significant negative correlation between 25 (OH) vitamin D level and disability of MS patients so that the disability reduces with increasing the 25 (OH) vitamin D level.
- multiple sclerosis,
- MS,
- disability,
- vitamin D,
- meta-analysis
Citation: Mahmood Moosazadeh, Fatemeh Nabinezhad-Male, Mahdi Afshari, Mohammad Mehdi Nasehi, Mohammad Shabani, Motahareh Kheradmand, Iraj Aghaei. Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis[J]. AIMS Neuroscience, 2021, 8(2): 239-253. doi: 10.3934/Neuroscience.2021013

Related Papers:

Abstract

Association between the serum vitamin D level and disability of patients with multiple sclerosis (MS) has been investigated during several researches. However, these studies reported different results. The current study aims to estimate the correlation between the concentrations of 25 (OH) vitamin D and the level of disability among MS patients. Using Mesh and non-Mesh terms related to MS, disability level and vitamin D, different data banks were searched. Required information was extracted from the selected eligible primary articles. Stata version 11 software was applied for combining the primary correlation coefficients using random effect model. The effect of MS type and patients' age was assessed using meta-regression models. Sensitivity analysis was performed to investigate the role of each primary study in the pooled estimate. Egger test was applied to find any publication bias. Of 14 eligible studies, the total correlation coefficient (95% confidence interval) between 25 (OH) vitamin D level and disability in both sexes as well as among female was estimated as of −0.29 (−0.40, −0.17) and −0.35 (−0.46, −0.24) respectively. Two articles carried out among male did not report significant results. Our meta-analysis showed a significant negative correlation between 25 (OH) vitamin D level and disability of MS patients so that the disability reduces with increasing the 25 (OH) vitamin D level.

Abbreviations

Multiple Sclerosis

EDSS

Expanded Disability Status Scale

NOS

New-Castle-Ottawa Scale

DBP

Vitamin D Binding Protein

PRMS

Progressive Relapsing Multiple Sclerosis

SRMS

Secondary Relapsing Multiple Sclerosis

Availability of supporting data

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author contributions

MM, MS, MA and MMN conceived and designed the study protocol. FN, MM, IA, MA and MK screened all the references, extracted the data, and wrote the paper. MMN and IA served as arbitrator in case of discrepancies during extraction and wrote the paper. All authors read and approved the final draft.

Conflict of interests

The authors declare no conflict of interest.

References

[1]	Koriem KMM (2016) Multiple sclerosis: New insights and trends. Asian Pac J Trop Biomed 6: 429-440. doi: 10.1016/j.apjtb.2016.03.009
[2]	Nakahara J, Maeda M, Aiso S, et al. (2012) Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol 42: 26-34. doi: 10.1007/s12016-011-8287-6
[3]	Lauer AA, Janitschke D, Hartmann T, et al. (2019) The Effects of Vitamin D Deficiency on Neurodegenerative Diseases. Vitam D Deficiency Available from: https://www.intechopen.com/books/vitamin-d-deficiency/the-effects-of-vitamin-d-deficiency-on-neurodegenerative-diseases.
[4]	Kheradmand M, Afshari M, Nasehi MM, et al. (2019) Prevalence of subtypes of multiple sclerosis and the most common clinical symptoms in Iranian patients: A meta-analysis. Clin Exp Neuroimmunol 10: 33-40. doi: 10.1111/cen3.12489
[5]	Rejdak K, Jackson S, Giovannoni G (2010) Multiple sclerosis: a practical overview for clinicians. Br Med Bull 95: 79-104. doi: 10.1093/bmb/ldq017
[6]	Wade BJ (2014) Spatial analysis of global prevalence of multiple sclerosis suggests need for an updated prevalence scale. Mult Scler Int 2014: 124578.
[7]	Kingwell E, Marriott JJ, Jetté N, et al. (2013) Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 13: 128. doi: 10.1186/1471-2377-13-128
[8]	Disanto G, Morahan JM, Ramagopalan SV (2012) Multiple sclerosis: risk factors and their interactions. CNS Neurol Disord Targets 11: 545-555. doi: 10.2174/187152712801661266
[9]	Wingerchuk DM (2011) Environmental factors in multiple sclerosis: epstein-Barr virus, vitamin D, and cigarette smoking. Mt Sinai J Med 78: 221-230. doi: 10.1002/msj.20240
[10]	Webb AR (2006) Who, what, where and when—influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 92: 17-25. doi: 10.1016/j.pbiomolbio.2006.02.004
[11]	Aranow C (2011) Vitamin D and the immune system. J Investig Med 59: 881-886. doi: 10.2310/JIM.0b013e31821b8755
[12]	Pierrot-Deseilligny C, Souberbielle JC (2010) Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain 133: 1869-1888. doi: 10.1093/brain/awq147
[13]	Meyer-Moock S, Feng YS, Maeurer M, et al. (2014) Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol 14: 58. doi: 10.1186/1471-2377-14-58
[14]	Fahmi RM, Lotfy SM, Mohamed WS, et al. (2014) Vitamin D levels in patients with multiple sclerosis. Egypt J Neurol Psychiatr Neurosurg 51: 145-152.
[15]	Kutlu A, Görür GD, Efendi H, et al. (2012) Vitamin D status in multiple sclerosis: Are there any correlations with the health related quality of life. Neurol Psychiatry Brain Res 18: 8-14. doi: 10.1016/j.npbr.2011.10.001
[16]	Nikanfar M, Taheri-Aghdam AA, Yazdani M, et al. (2015) Serum 25 (OH) Vitamin D levels is not associated with disability in multiple sclerosis patients: A case-control study. Iran J Neurol 14: 17-21.
[17]	Brola W, Sobolewski P, Szczuchniak W, et al. (2016) Association of seasonal serum 25-hydroxyvitamin D levels with disability and relapses in relapsing-remitting multiple sclerosis. EurJ Clin Nutr 70: 995-999. doi: 10.1038/ejcn.2016.51
[18]	Garg AX, Hackam D, Tonelli M (2008) Systematic review and meta-analysis: when one study is just not enough. Clin J Am Soc Nephrol 3: 253-260. doi: 10.2215/CJN.01430307
[19]	Liberati A, Altman DG, Tetzlaff J, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62: 1-34. doi: 10.1016/j.jclinepi.2009.06.006
[20]	Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. EurJ Epidemiol 25: 603-605. doi: 10.1007/s10654-010-9491-z
[21]	Bettencourt A, Boleixa D, Reguengo H, et al. (2018) Serum 25-hydroxyvitamin D levels in multiple sclerosis patients from the north of Portugal. J Steroid Biochem Mol Biol 180: 137-141. doi: 10.1016/j.jsbmb.2017.09.016
[22]	Fragoso YD, Adoni T, Alves-Leon SV, et al. (2017) No correlation was observed between vitamin D levels and disability of patients with multiple sclerosis between latitudes 18 and 30 South. Arq Neuropsiquiatr 75: 3-8. doi: 10.1590/0004-282x20160173
[23]	Harandi AA, Shahbeigi S, Pakdaman H, et al. (2012) Association of serum 25 (OH) vitamin D3 concentration with severity of multiple sclerosis. Iran J Neurol 11: 54-58.
[24]	Karampoor S, Zahednasab H, Ramagopalan S, et al. (2016) 25-hydroxyvitamin D levels are associated with multiple sclerosis in Iran: A cross-sectional study. J Neuroimmunol 290: 47-48. doi: 10.1016/j.jneuroim.2015.11.017
[25]	Kragt J, Van Amerongen B, Killestein J, et al. (2009) Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 15: 9-15. doi: 10.1177/1352458508095920
[26]	Rito Y, Flores J, Fernández-Aguilar A, et al. (2018) Vitamin D and disability in relapsing–remitting multiple sclerosis in patients with a Mexican background. Acta Neurol Belg 118: 47-52. doi: 10.1007/s13760-017-0834-3
[27]	Shahbeigi S, Pakdaman H, Fereshtehnejad SM, et al. (2013) Vitamin d3 concentration correlates with the severity of multiple sclerosis. Int J Prev Med 4: 585-591.
[28]	Thouvenot E, Orsini M, Daures JP, et al. (2015) Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis. Eur J Neurol 22: 564-569. doi: 10.1111/ene.12617
[29]	Van der Mei IAF, Ponsonby AL, Dwyer T, et al. (2007) Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254: 581-590. doi: 10.1007/s00415-006-0315-8
[30]	Zamzam DA, Fouad MM, Elaidy DA, et al. (2016) Vitamin D levels in a sample of Egyptian patients with multiple sclerosis. Egypt J Neurol Psychiatry Neurosurg 53: 107-110. doi: 10.4103/1110-1083.183437
[31]	Tsuprykov O, Chen X, Hocher CF, et al. (2018) Why should we measure free 25 (OH) vitamin D? J Steroid Biochem Mol Biol 180: 87-104. doi: 10.1016/j.jsbmb.2017.11.014
[32]	Trojano M, Lucchese G, Graziano G, et al. (2012) Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One 7: e48078. doi: 10.1371/journal.pone.0048078
[33]	Ribbons KA, McElduff P, Boz C, et al. (2015) Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS. PloS One 10: e0122686. doi: 10.1371/journal.pone.0122686
[34]	Jassil NK, Sharma A, Bikle D, et al. (2017) Vitamin D binding protein and 25-hydroxyvitamin D levels: emerging clinical applications. Endocr Practi 23: 605-613. doi: 10.4158/EP161604.RA
[35]	White P, Cooke N (2000) The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinology Metab 11: 320-327. doi: 10.1016/S1043-2760(00)00317-9
[36]	Rinaldi AO, Sanseverino I, Purificato C, et al. (2015) Increased circulating levels of vitamin D binding protein in MS patients. Toxins 7: 129-137. doi: 10.3390/toxins7010129
[37]	Bhan I (2014) Vitamin d binding protein and bone health. Int J Endocrinol 2014. doi: 10.1155/2014/561214
[38]	Sollid ST, Hutchinson MYS, Berg V, et al. (2016) Effects of vitamin D binding protein phenotypes and vitamin D supplementation on serum total 25 (OH) D and directly measured free 25 (OH) D. Eur J Endocrinol 174: 445-452. doi: 10.1530/EJE-15-1089
[39]	Matloff DS, Kaplan MM, Neer RM, et al. (1982) Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 83: 97-102. doi: 10.1016/S0016-5085(82)80291-6
[40]	Doorenbos CR, Milton M, Vogt L, et al. (2012) Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. J Steroid Biochem Mol Biol 128: 56-61. doi: 10.1016/j.jsbmb.2011.09.002
[41]	Dupuis ML, Pagano MT, Pierdominici M, et al. (2021) The role of vitamin D in autoimmune diseases: could sex make the difference? Biol Sex Differ 12: 12. doi: 10.1186/s13293-021-00358-3
[42]	Luchetti S, van Eden CG, Schuurman K, et al. (2014) Gender differences in multiple sclerosis: induction of estrogen signaling in male and progesterone signaling in female lesions. J Neuropathol Exp Neurol 73: 123-135. doi: 10.1097/NEN.0000000000000037
[43]	Hashemi R, Morshedi M, Jafarabadi MA, et al. (2018) Anti-inflammatory effects of dietary vitamin D3 in patients with multiple sclerosis. Neurol Genet 4: e278. doi: 10.1212/NXG.0000000000000278
[44]	Farghali M, Ruga S, Morsanuto V, et al. (2020) Can Brain Health Be Supported by Vitamin D-Based Supplements? A Critical Review. Brain Sci 10: 660. doi: 10.3390/brainsci10090660
[45]	Behrens JR, Rasche L, Gieß RM, et al. (2016) Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis. Eur J Neurol 23: 62-67. doi: 10.1111/ene.12788
[46]	Sintzel MB, Rametta M, Reder AT (2018) Vitamin D and multiple sclerosis: a comprehensive review. Neurol Ther 7: 59-85. doi: 10.1007/s40120-017-0086-4
[47]	Smolders J, Menheere P, Kessels A, et al. (2008) Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 14: 1220-1224. doi: 10.1177/1352458508094399
[48]	Al-Mahdawi AM, Al Gawwam G, Al Ethawi RA (2014) Association of vitamin D Metabolite levels with relapse rate and disability in multiple sclerosis. Iraqi Acad Sci J 3: 298-305.
[49]	Mowry EM, Waubant E, McCulloch CE, et al. (2012) Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 72: 234-240. doi: 10.1002/ana.23591
[50]	Martinelli V, Dalla Costa G, Colombo B, et al. (2014) Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 20: 147-155. doi: 10.1177/1352458513494959

Reader Comments

Your name:*

Email:*
© 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)